<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11344233</article-id><article-id pub-id-type="pmcid-ver">PMC11344233.1</article-id><article-id pub-id-type="pmcaid">11344233</article-id><article-id pub-id-type="pmcaiid">11344233</article-id><article-id pub-id-type="pmid">39177985</article-id><article-id pub-id-type="doi">10.1001/jamahealthforum.2024.2647</article-id><article-id pub-id-type="publisher-id">abr240008</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Public Health Impact of FDA&#8217;s Request for Additional Safety Data on Cytisine for Tobacco Cessation</article-title><alt-title alt-title-type="headline">Public Health Impact of FDA&#8217;s Request for Additional Safety Data on Cytisine for Tobacco Cessation</alt-title><alt-title alt-title-type="running-head">Public Health Impact of FDA&#8217;s Request for Additional Safety Data on Cytisine for Tobacco Cessation</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Reddy</surname><given-names initials="KP">Krishna P.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="abr240008aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="abr240008aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="abr240008aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="abr240008aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paltiel</surname><given-names initials="AD">A. David</given-names></name><degrees>MBA</degrees><degrees>PhD</degrees><xref rid="abr240008aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Freedberg</surname><given-names initials="KA">Kenneth A.</given-names></name><degrees>MD</degrees><degrees>MSc</degrees><xref rid="abr240008aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="abr240008aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="abr240008aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="abr240008aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="abr240008aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rigotti</surname><given-names initials="NA">Nancy A.</given-names></name><degrees>MD</degrees><xref rid="abr240008aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="abr240008aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="abr240008aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="abr240008aff1"><label>1</label>Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Boston</aff><aff id="abr240008aff2"><label>2</label>Tobacco Research and Treatment Center, Mongan Institute, Massachusetts General Hospital, Boston</aff><aff id="abr240008aff3"><label>3</label>Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston</aff><aff id="abr240008aff4"><label>4</label>Harvard Medical School, Boston, Massachusetts</aff><aff id="abr240008aff5"><label>5</label>Public Health Modeling Unit, Yale School of Public Health, New Haven, Connecticut</aff><aff id="abr240008aff6"><label>6</label>Division of General Internal Medicine, Massachusetts General Hospital, Boston</aff><aff id="abr240008aff7"><label>7</label>Division of Infectious Diseases, Massachusetts General Hospital, Boston</aff><aff id="abr240008aff8"><label>8</label>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> June 27, 2024.</p><p content-type="published-online"><bold>Published:</bold> August 23, 2024. doi:<uri content-type="doi">10.1001/jamahealthforum.2024.2647</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2024 Reddy KP et al. <italic toggle="yes">JAMA Health Forum</italic>.</p><corresp id="abr240008cor1"><bold>Corresponding Author:</bold> Krishna P. Reddy, MD, MS, Massachusetts General Hospital, 100 Cambridge St, Ste 1600, Boston, MA 02114 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kpreddy@mgh.harvard.edu">kpreddy@mgh.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Reddy had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Reddy, Paltiel, Rigotti.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Reddy, Paltiel, Freedberg.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Reddy, Rigotti.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Paltiel, Freedberg, Rigotti.</p><p><italic toggle="yes">Statistical analysis:</italic> Reddy.</p><p><italic toggle="yes">Obtained funding:</italic> Reddy.</p><p><italic toggle="yes">Supervision:</italic> Rigotti.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Reddy reported a grant from the American Lung Association during the conduct of the study; and royalties for authorship from UpToDate outside the submitted work. Dr Rigotti reported grants and personal fees from Achieve Life Sciences prior to but not during the conduct of this study. She received no funds from Achieve Life Sciences for preparing or working on this manuscript. Achieve Life Sciences had no role in the conception or conduct of this study or in manuscript preparation. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by Innovation Award IA-834584 from the American Lung Association to K.P.R.</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding source.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ABR240008-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p><p><bold>Additional Contributions:</bold> We thank Julie Deleger, BA, Massachusetts General Hospital, for assistance with the literature review. She was not compensated.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-08-23T10:00"><day>23</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>5</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">469342</issue-id><elocation-id>e242647</elocation-id><history><date date-type="received"><day>15</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-29 02:26:00.763"><day>29</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 Reddy KP et al. <italic toggle="yes">JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamahealthforum-e242647.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamahealthforum-e242647.pdf">jamahealthforum-e242647.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2024.2647"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-abr240008-1"><title>Question</title><p>What is the potential public health impact of cytisine, and delays in its availability, as a new tobacco smoking cessation aid in the US?</p></sec><sec id="ab-abr240008-2"><title>Findings</title><p>In a mathematical model, making cytisine available immediately could lead approximately 71&#8201;000 more people to quit smoking over 1 year and maintain long-term abstinence, producing more than 500&#8201;000 additional life-years. Each additional year of delay in the availability of cytisine might reduce population-level life expectancy by 10&#8201;000 years.</p></sec><sec id="ab-abr240008-3"><title>Meaning</title><p>Cytisine could have major public health benefits, including lengthening population-level life expectancy; therefore, a timely review of cytisine for approval in the US is warranted.</p></sec></abstract><abstract><sec id="ab-abr240008-4"><title>Importance</title><p>No new tobacco cessation medication has been licensed in the US since 2006. Cytisine, a plant-based partial agonist of nicotinic acetylcholine receptors, has demonstrated safety and efficacy in several randomized clinical trials and is currently available in many countries. However, the drug is not commercially available in the US. A New Drug Application to license cytisine as a smoking cessation medication in the US is being prepared for review by the US Food and Drug Administration, whose request for additional safety data will delay submission of the application by approximately 1 year.</p></sec><sec id="ab-abr240008-5"><title>Objective</title><p>To project the potential public health impact of cytisine, and delays in its availability, as a smoking cessation aid in the US.</p></sec><sec id="ab-abr240008-6"><title>Design, Setting, and Participants</title><p>This mathematical model estimated life expectancy gains from smoking cessation for people aged 18 to 99 years in the US, reflecting the civilian, noninstitutionalized population. The model also accounted for cytisine uptake and effectiveness, as well as potential relapse among people who stop smoking.</p></sec><sec id="ab-abr240008-7"><title>Exposure</title><p>Cytisine availability as a tobacco cessation treatment immediately or after 1 year.</p></sec><sec id="ab-abr240008-8"><title>Main Outcomes and Measures</title><p>The main outcomes were the number of adults able to stop smoking and sustain long-term abstinence and aggregate life-years gained.</p></sec><sec id="ab-abr240008-9"><title>Results</title><p>The base case includes an estimated 29.4 million US civilian noninstitutionalized adults who smoke cigarettes (age distribution, 18-24 years: 5.5%; 25-44 years: 37.3%; 45-64 years: 41.8%; &#8805;65 years: 15.5%). With a conservative assumption that 3.8% of these individuals would use cytisine in the first year of availability, immediate cytisine availability could lead 71&#8201;000 more people to quit smoking over 1 year and maintain long-term abstinence. This would produce more than 500&#8201;000 additional life-years compared to the status quo in which cytisine is unavailable and fewer people stop smoking. Each additional year of delay in the availability of cytisine might reduce population-level life expectancy by 10&#8201;000 years. The model results were most sensitive to changes in cytisine uptake and effectiveness.</p></sec><sec id="ab-abr240008-10"><title>Conclusions and Relevance</title><p>Smoking cessation generates large gains in life expectancy. This mathematical model demonstrated that immediate cytisine availability, even if used successfully by only a small fraction of people who smoke, could produce major public health benefits. Given the need for new tobacco cessation pharmacotherapy options, the magnitude of cytisine&#8217;s potential public health benefits, and the morbidity and mortality associated with delay in its availability, a timely review of cytisine for approval in the US is warranted.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This mathematical model projects the potential population-level health impacts of making cytisine immediately available as an approved smoking cessation aid in the US vs delaying approval by 1 year.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ABR240008"><title>Introduction</title><p>Tobacco smoking is the leading preventable cause of death in the US.<sup><xref rid="abr240008r1" ref-type="bibr">1</xref></sup> Approximately two-thirds of US adults who smoke report wanting to stop.<sup><xref rid="abr240008r2" ref-type="bibr">2</xref></sup> No new tobacco cessation medication has been licensed in the US since 2006. Cytisine, a plant-based partial agonist of nicotinic acetylcholine receptors, has been used to treat tobacco dependence for decades.<sup><xref rid="abr240008r3" ref-type="bibr">3</xref></sup> It is available as a generic or prescription medication in at least 18 countries, was licensed as an over-the-counter natural health product in Canada in 2017, and became available by prescription in the UK in January 2024.<sup><xref rid="abr240008r4" ref-type="bibr">4</xref>,<xref rid="abr240008r5" ref-type="bibr">5</xref></sup> In the US, however, it is neither approved for use nor commercially available.</p><p>Recent events threaten the timely US regulatory review of cytisine. Cytisine&#8217;s US manufacturer planned to submit an application to the US Food and Drug Administration (FDA) for approval of cytisinicline (cytisine&#8217;s newer generic name) as a prescription smoking cessation aid in early 2024.<sup><xref rid="abr240008r6" ref-type="bibr">6</xref></sup> That application included evidence from a US randomized clinical trial reporting 5 times higher odds of tobacco abstinence at 24 weeks for cytisinicline plus behavioral counseling vs placebo plus counseling (odds ratio, 5.3 [95% CI, 2.8-11.1]). The study demonstrated no serious drug-related adverse events.<sup><xref rid="abr240008r7" ref-type="bibr">7</xref></sup> However, the FDA requested additional data supporting the safety of longer drug administration, delaying the application&#8217;s review by at least 1 year.<sup><xref rid="abr240008r8" ref-type="bibr">8</xref></sup> We estimated the potential life expectancy losses associated with a 1-year delay in the FDA&#8217;s consideration of cytisine&#8217;s approval.</p></sec><sec id="H1-2-ABR240008"><title>Methods</title><p>We developed a mathematical model to estimate US life expectancy gains from smoking cessation at different ages (<xref rid="note-ABR240008-1-s" ref-type="supplementary-material">Supplement 1</xref> and <xref rid="note-ABR240008-1-s" ref-type="supplementary-material">Supplement 2</xref>). The model accounted for cytisine uptake and effectiveness, noting background levels of smoking cessation and relapse (<xref rid="abr240008t1" ref-type="table">Table 1</xref>).<sup><xref rid="abr240008r2" ref-type="bibr">2</xref>,<xref rid="abr240008r9" ref-type="bibr">9</xref>,<xref rid="abr240008r10" ref-type="bibr">10</xref>,<xref rid="abr240008r11" ref-type="bibr">11</xref>,<xref rid="abr240008r12" ref-type="bibr">12</xref>,<xref rid="abr240008r13" ref-type="bibr">13</xref>,<xref rid="abr240008r14" ref-type="bibr">14</xref></sup> To capture the outcomes of delayed cytisine approval, we considered immediate treatment initiation and initiation delayed by 1 year. This work followed the Consolidated Health Economic Evaluation Reporting Standards (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.equator-network.org/reporting-guidelines/cheers/" ext-link-type="uri">CHEERS</ext-link>) reporting guideline. It was designated as not human participant research by the Mass General Brigham Human Research Committee. Informed consent was waived per 45 CFR &#167; 46.116.</p><table-wrap position="float" id="abr240008t1" orientation="portrait"><label>Table 1. </label><caption><title>Model Input Parameters for Assessing the Health Impact of Immediate vs Delayed Cytisine Availability for Tobacco Cessation</title></caption><table frame="hsides" rules="groups"><col width="37.5%" span="1"/><col width="26.51%" span="1"/><col width="18.07%" span="1"/><col width="17.92%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Parameter</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Base case value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Range used in sensitivity analysis</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prevalence of cigarette smoking in the US in 2021 by age<xref rid="abr240008t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"><list list-type="simple"><list-item><p> Age, 18-24 y: 5.3%</p></list-item><list-item><p> Age, 25-44 y: 12.6%</p></list-item><list-item><p> Age, 45-64 y: 14.9%</p></list-item><list-item><p> Age, &#8805;65 y: 8.3%</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Cornelius et al<sup><xref rid="abr240008r9" ref-type="bibr">9</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Background probability of smoking cessation and abstinence for at least 1 y by age<xref rid="abr240008t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"><list list-type="simple"><list-item><p> Age, 18-24 y: 9.9%</p></list-item><list-item><p> Age, 25-44 y: 8.9%</p></list-item><list-item><p> Age, 45-64 y: 5.7%</p></list-item><list-item><p> Age, &#8805;65 y: 5.4%</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Babb et al<sup><xref rid="abr240008r2" ref-type="bibr">2</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Relative effectiveness of cytisine: probability of smoking cessation and abstinence for at least 1 y compared with background<xref rid="abr240008t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">1.1-2.5</td><td valign="top" align="left" rowspan="1" colspan="1">Lindson et al,<sup><xref rid="abr240008r10" ref-type="bibr">10</xref></sup> assumption<xref rid="abr240008t1n4" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Uptake of cytisine in 1 y among people who smoke</td><td valign="top" align="left" rowspan="1" colspan="1">3.8%</td><td valign="top" align="left" rowspan="1" colspan="1">1%-10%</td><td valign="top" align="left" rowspan="1" colspan="1">Moore et al<sup><xref rid="abr240008r11" ref-type="bibr">11</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Relapse probability after &#8805;1 y of smoking abstinence</td><td valign="top" align="left" rowspan="1" colspan="1">10%</td><td valign="top" align="left" rowspan="1" colspan="1">5%-20%</td><td valign="top" align="left" rowspan="1" colspan="1">Hughes et al<sup><xref rid="abr240008r12" ref-type="bibr">12</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Life expectancy gain from smoking cessation by age at quit<xref rid="abr240008t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p> Quit at age &lt;35 y: 10 y</p></list-item><list-item><p> Quit at age 40 y: 9 y</p></list-item><list-item><p> Quit at age 50 y: 6 y</p></list-item><list-item><p> Quit at age 60 y: 4 y</p></list-item><list-item><p> Quit at age 70 y: 1.5 y</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Jha et al<sup><xref rid="abr240008r13" ref-type="bibr">13</xref></sup> and Jia et al<sup><xref rid="abr240008r14" ref-type="bibr">14</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Abbreviation: NA, not applicable.</p><fn id="abr240008t1n1"><label>
<sup>a</sup>
</label><p>Data are shown from the National Health Interview Survey for the civilian, noninstitutionalized population.</p></fn><fn id="abr240008t1n2"><label>
<sup>b</sup>
</label><p>The background probability of smoking cessation is among all people who smoke in a scenario without cytisine available.</p></fn><fn id="abr240008t1n3"><label>
<sup>c</sup>
</label><p>The relative effectiveness of cytisine is applied as a multiplier to the background probability of smoking cessation among people who use cytisine.</p></fn><fn id="abr240008t1n4"><label>
<sup>d</sup>
</label><p>Values were approximations based on the range of effectiveness reported in various studies, including the meta-analysis by Lindson et al.<sup><xref rid="abr240008r10" ref-type="bibr">10</xref></sup></p></fn><fn id="abr240008t1n5"><label>
<sup>e</sup>
</label><p>Linear interpolation was performed between these quit ages to derive the life expectancy gained from smoking cessation at different ages. For example, people who quit at 45 years of age would gain 7.5 years of life expectancy. We modeled gains in life expectancy for people who quit smoking by 77 years of age; no gain in life expectancy was assumed for people who quit smoking at 78 years or older.<sup><xref rid="abr240008r14" ref-type="bibr">14</xref></sup></p></fn></table-wrap-foot></table-wrap><p>To determine the number of people who smoke and their age distribution, we used 2021 data from the National Health Interview Survey (NHIS) and the Census.<sup><xref rid="abr240008r9" ref-type="bibr">9</xref></sup> Our analysis included adults aged between 18 and 99 years.</p><p>We reviewed historical data about varenicline, a drug with a similar mechanism of action, to determine the number of people who might use cytisine. By 2008, approximately 2 years after FDA approval, varenicline was used by 3.5 million US adults (7.6% of people who smoked).<sup><xref rid="abr240008r11" ref-type="bibr">11</xref>,<xref rid="abr240008r15" ref-type="bibr">15</xref></sup> We conservatively halved this proportion to 3.8% to estimate cytisine uptake over 1 year.</p><p>We estimated that without cytisine, the age-dependent annual probability of quitting and maintaining abstinence for at least 1 year would be 5.4% to 9.9%; based on data from a meta-analysis, we assumed that cytisine would double this probability (<xref rid="abr240008t1" ref-type="table">Table 1</xref>).<sup><xref rid="abr240008r2" ref-type="bibr">2</xref>,<xref rid="abr240008r10" ref-type="bibr">10</xref></sup> We applied a 10% probability of smoking relapse after 1 year of abstinence.<sup><xref rid="abr240008r12" ref-type="bibr">12</xref></sup></p><p>For life expectancy gains from smoking cessation at different ages (compared with continued smoking), we used data from the NHIS, the linked National Death Index, and the Medicare Health Outcome Survey (eMethods in <xref rid="note-ABR240008-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="abr240008r13" ref-type="bibr">13</xref>,<xref rid="abr240008r14" ref-type="bibr">14</xref></sup> We assumed that only people who maintain long-term abstinence experience these gains.</p><p>To evaluate the impact of delay in availability, we recalculated aggregate life expectancy gains assuming that cytisine-aided smoking cessation occurred 1 year later. For example, a 45-year-old individual who would initiate cytisine if immediately available would instead initiate cytisine at 46 years. The life expectancy gain would be reduced from 7.5 years to 7.2 years, reflecting the later age at quitting.</p><p>In sensitivity analysis, we varied cytisine uptake, cytisine&#8217;s effectiveness, and relapse probability (<xref rid="abr240008t1" ref-type="table">Table 1</xref>). We evaluated pessimistic and optimistic scenarios, simultaneously setting these parameters to minimize and maximize cytisine&#8217;s estimated impact.</p></sec><sec id="H1-3-ABR240008"><title>Results</title><p>The base case includes an estimated 29.4 million US civilian noninstitutionalized adults who smoke cigarettes (age distribution, 18-24 years: 5.5%; 25-44 years: 37.3%; 45-64 years: 41.8%; &#8805;65 years: 15.5%). An estimated 1.87 million of these individuals would stop smoking annually and maintain long-term abstinence without cytisine. With a conservative assumption that 3.8% of these individuals would use cytisine in the first year of availability, an estimated 1.12 million people would use the drug in 1 year, and the number of long-term abstainers would increase by 71&#8201;000, to 1.94 million. The population-level life-years gained, compared to continued smoking, would increase by 503&#8201;000, from 13.23 million (cytisine unavailable) to 13.73 million (cytisine immediately available). If cytisine availability were delayed by 1 year, 10&#8201;000 fewer life-years would be gained (<xref rid="abr240008t2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="abr240008t2" orientation="portrait"><label>Table 2. </label><caption><title>Base Case and Sensitivity Analysis Results for Tobacco Cessation and Life-Year Gains Based on Cytisine Availability<xref rid="abr240008t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="29.17%" span="1"/><col width="16.53%" span="1"/><col width="27.68%" span="1"/><col width="26.62%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Analysis (base case value; range)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">New abstainers<xref rid="abr240008t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Aggregate life-years gained through smoking cessation</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Immediate cytisine availability vs status quo<xref rid="abr240008t2n3" ref-type="table-fn"><sup>c</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Delayed cytisine availability vs status quo<xref rid="abr240008t2n3" ref-type="table-fn"><sup>c</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Base case</td><td valign="top" align="left" rowspan="1" colspan="1">71&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">503&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">493&#8201;000</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sensitivity to cytisine uptake (3.8%; 1%-10%)<xref rid="abr240008t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;000-187&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">132&#8201;000-1&#8201;323&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sensitivity to cytisine effectiveness (2; 1.1-2.5)<xref rid="abr240008t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">7000-107&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">50&#8201;000-754&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sensitivity to long-term relapse (10%; 20%-5%)<xref rid="abr240008t2n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">63&#8201;000-75&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">447&#8201;000-531&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pessimistic scenario to optimistic scenario, range<xref rid="abr240008t2n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2000-296&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;000-2&#8201;095&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: NA, not applicable.</p><fn id="abr240008t2n1"><label>
<sup>a</sup>
</label><p>Results reflect cytisine uptake over 1 year for 2 scenarios, immediate cytisine availability or delayed cytisine availability by 1 year, as well as the downstream health impact. Model results are rounded to the nearest thousand.</p></fn><fn id="abr240008t2n2"><label>
<sup>b</sup>
</label><p>This is the increase in the number of people who would quit smoking and maintain long-term abstinence with cytisine, compared to the status quo scenario in which cytisine is not available but there is background smoking cessation.</p></fn><fn id="abr240008t2n3"><label>
<sup>c</sup>
</label><p>These reflect aggregate life-year gains by the additional people who would stop smoking in scenarios of immediate cytisine availability or delayed cytisine availability compared with the status quo scenario in which cytisine is not available but there is background smoking cessation.</p></fn><fn id="abr240008t2n4"><label>
<sup>d</sup>
</label><p>This is the proportion of all people who smoke who would use cytisine.</p></fn><fn id="abr240008t2n5"><label>
<sup>e</sup>
</label><p>Cytisine effectiveness is measured as a multiplier relative to background smoking cessation probabilities, which reflect both users and nonusers of available pharmacotherapies.</p></fn><fn id="abr240008t2n6"><label>
<sup>f</sup>
</label><p>Relapse is measured as a probability and applied to both the status quo scenario and the scenario in which cytisine is available.</p></fn><fn id="abr240008t2n7"><label>
<sup>g</sup>
</label><p>The pessimistic scenario assumes that 1% of people who smoke use cytisine, the relative effectiveness of cytisine is 1.1, and the relapse probability is 20%. The optimistic scenario assumes that 10% of people who smoke use cytisine, relative effectiveness of cytisine is 2.5, and relapse probability is 5%.</p></fn></table-wrap-foot></table-wrap><p>In the sensitivity analysis, cytisine uptake and effectiveness were estimated to have the largest impact on results. Relapse probability, which could affect both status quo and cytisine scenarios, is less influential (<xref rid="abr240008t2" ref-type="table">Table 2</xref>). In the pessimistic or optimistic scenarios, immediate cytisine availability was estimated to produce 2000 or 296&#8201;000 additional long-term abstainers and 12&#8201;000 or 2.095 million aggregate life-years gained, respectively.</p></sec><sec id="H1-4-ABR240008"><title>Discussion</title><p>Using a mathematical model, we found that if cytisine were made immediately available in the US and used over 1 year by 3.8% of adults who smoke, more than 500&#8201;000 additional life-years were estimated due to increased smoking cessation rates compared with background cessation. Each 1-year delay in cytisine availability could result in 10&#8201;000 fewer life-years gained.</p><p>New smoking cessation pharmacotherapy options are urgently needed in the US. Utilization of existing FDA-approved pharmacotherapies, such as nicotine replacement products, varenicline, and bupropion, is limited by prior unsuccessful use, concerns about potential adverse effects, supply constraints, and cost. Cytisine may be appealing to many as a naturally derived product, and multiple studies have demonstrated its safety and efficacy.<sup><xref rid="abr240008r7" ref-type="bibr">7</xref>,<xref rid="abr240008r10" ref-type="bibr">10</xref></sup></p><p>In our base case analysis, we assumed that only approximately 0.5% of US adults who smoke would attain long-term abstinence using cytisine, and only half of these would benefit from cytisine over current cessation practices. Despite these small proportions, both the total number of people who might benefit (71&#8201;000) and the potential life-year gains (more than 500&#8201;000) are large, the latter because of the major impact of smoking and smoking cessation on life expectancy.<sup><xref rid="abr240008r13" ref-type="bibr">13</xref></sup> Cessation at older ages still improves life expectancy, but quitting earlier provides greater benefit.<sup><xref rid="abr240008r13" ref-type="bibr">13</xref></sup></p><p>Although long-term drug outcome surveillance is important, we believe that making cytisine available sooner will outweigh the potential disadvantages. First, cytisine has a similar mechanism of action to varenicline, a drug with abundant long-term evidence of safety and efficacy. Indeed, initial reports suggest troubling adverse effects like nausea occur less frequently with cytisine than with varenicline.<sup><xref rid="abr240008r5" ref-type="bibr">5</xref>,<xref rid="abr240008r7" ref-type="bibr">7</xref>,<xref rid="abr240008r10" ref-type="bibr">10</xref></sup> Second, cytisine has been available for many years in other countries, including Canada, without reports of serious cytisine-related adverse effects.<sup><xref rid="abr240008r3" ref-type="bibr">3</xref>,<xref rid="abr240008r16" ref-type="bibr">16</xref></sup> Third, the impact of the more common adverse effects associated with cytisine (and varenicline), such as abnormal dreams and insomnia, is likely to be far outweighed by the benefits of earlier smoking cessation.</p><sec id="H2-1-ABR240008"><title>Limitations</title><p>This study was limited by the uncertainty in the data inputs and assumptions underlying our projections. Potential cytisine uptake is unknown. Nonetheless, if only 1% of US adults who smoke use cytisine over 1 year, instead of 3.8% as assumed in the base case, 132&#8201;000 life-years could be gained. Our projections also depend on cytisine&#8217;s effectiveness. If cytisine were used only by people who would otherwise use other available pharmacotherapies, its relative effectiveness could be lower than assumed in the base case, where we compared cytisine to background quitting including users and nonusers of available pharmacotherapies. We found that cytisine would still have an important impact on health outcomes even with lower relative effectiveness. Cytisine uptake may also vary across subpopulations of people who smoke, but exactly how remains uncertain. Few published data exist about life expectancy gains from stopping smoking at 65 years or older.<sup><xref rid="abr240008r14" ref-type="bibr">14</xref></sup></p></sec></sec><sec id="H1-5-ABR240008"><title>Conclusions</title><p>Even if used by only a small proportion of US adults who smoke tobacco, this mathematical model found that cytisine could have a major impact on public health outcomes. Because quitting sooner is associated with greater life expectancy gains, delayed cytisine availability could decrease health benefits. These findings suggest that a timely FDA review of cytisine is warranted. Delays in the FDA decision could undermine population benefits.</p></sec></body><back><ref-list id="REF-ABR240008"><title>References</title><ref id="abr240008r1"><label>1</label><mixed-citation publication-type="webpage"><person-group><collab>US Department of Health and Human Services</collab></person-group>. The health consequences of smoking-50 years of progress: a report of the Surgeon General. <year>2014</year>. Accessed July 24, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html" ext-link-type="uri">https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html</ext-link></mixed-citation></ref><ref id="abr240008r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Babb</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Malarcher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schauer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Asman</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jamal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Quitting smoking among adults&#8212;United States, 2000-2015</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2017</year>;<volume>65</volume>(<issue>52</issue>):<fpage>1457</fpage>-<lpage>1464</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6552a1</pub-id><pub-id pub-id-type="pmid">28056007</pub-id></mixed-citation></ref><ref id="abr240008r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tutka</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vinnikov</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Courtney</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></string-name></person-group>. <article-title>Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation</article-title>. <source>Addiction</source>. <year>2019</year>;<volume>114</volume>(<issue>11</issue>):<fpage>1951</fpage>-<lpage>1969</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.14721</pub-id><pub-id pub-id-type="pmid">31240783</pub-id></mixed-citation></ref><ref id="abr240008r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Walker</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bullen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Getting cytisine licensed for use world-wide: a call to action</article-title>. <source>Addiction</source>. <year>2016</year>;<volume>111</volume>(<issue>11</issue>):<fpage>1895</fpage>-<lpage>1898</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.13464</pub-id><pub-id pub-id-type="pmid">27426482</pub-id></mixed-citation></ref><ref id="abr240008r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ofori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olasupo</surname><given-names>OO</given-names></string-name>, <etal/></person-group>. <article-title>Cytisine for smoking cessation: a systematic review and meta-analysis</article-title>. <source>Drug Alcohol Depend</source>. <year>2023</year>;<volume>251</volume>:<elocation-id>110936</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.110936</pub-id><pub-id pub-id-type="pmid">37678096</pub-id></mixed-citation></ref><ref id="abr240008r6"><label>6</label><mixed-citation publication-type="webpage"><person-group><collab>Achieve Life Sciences</collab></person-group>. Achieve Life Sciences reports financial results for sec quarter 2023 and provides corporate update. Published August 14, <year>2023</year>. Accessed April 11, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://achievelifesciences.com/achieve-reports-2q23-financial-results/" ext-link-type="uri">https://achievelifesciences.com/achieve-reports-2q23-financial-results/</ext-link></mixed-citation></ref><ref id="abr240008r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rigotti</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Prochaska</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Cytisinicline for smoking cessation: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>(<issue>2</issue>):<fpage>152</fpage>-<lpage>160</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2023.10042</pub-id><pub-id pub-id-type="pmid">37432430</pub-id><pub-id pub-id-type="pmcid">PMC10336611</pub-id></mixed-citation></ref><ref id="abr240008r8"><label>8</label><mixed-citation publication-type="webpage"><person-group><collab>Achieve Life Sciences</collab></person-group>. Achieve Life Sciences reaches agreement with the FDA on long-term cytisinicline exposure data requirements for NDA submission. Published February 29, <year>2024</year>. Accessed April 11, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://achievelifesciences.com/achieve-reaches-agreement-with-fda-on-long-term-cytisinicline-exposure-data-requirements-for-nda/" ext-link-type="uri">https://achievelifesciences.com/achieve-reaches-agreement-with-fda-on-long-term-cytisinicline-exposure-data-requirements-for-nda/</ext-link></mixed-citation></ref><ref id="abr240008r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cornelius</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Loretan</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Jamal</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Tobacco product use among adults&#8212;United States, 2021</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2023</year>;<volume>72</volume>(<issue>18</issue>):<fpage>475</fpage>-<lpage>483</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm7218a1</pub-id><pub-id pub-id-type="pmid">37141154</pub-id><pub-id pub-id-type="pmcid">PMC10168602</pub-id></mixed-citation></ref><ref id="abr240008r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lindson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Theodoulou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ord&#243;&#241;ez-Mena</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2023</year>;<volume>9</volume>(<issue>9</issue>):<elocation-id>CD015226</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD015226.pub2</pub-id><pub-id pub-id-type="pmid">37696529</pub-id><pub-id pub-id-type="pmcid">PMC10495240</pub-id></mixed-citation></ref><ref id="abr240008r11"><label>11</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Moore</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Furberg</surname><given-names>CD</given-names></string-name></person-group>. Strong safety signal seen for new varenicline risks. The Institute for Safe Medication Practices. Accessed July 24, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ismp.org/sites/default/files/attachments/2018-01/2007Q4.pdf" ext-link-type="uri">https://www.ismp.org/sites/default/files/attachments/2018-01/2007Q4.pdf</ext-link></mixed-citation></ref><ref id="abr240008r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hughes</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Naud</surname><given-names>S</given-names></string-name></person-group>. <article-title>Relapse to smoking after 1 year of abstinence: a meta-analysis</article-title>. <source>Addict Behav</source>. <year>2008</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1516</fpage>-<lpage>1520</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addbeh.2008.05.012</pub-id><pub-id pub-id-type="pmid">18706769</pub-id><pub-id pub-id-type="pmcid">PMC2577779</pub-id></mixed-citation></ref><ref id="abr240008r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jha</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ramasundarahettige</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Landsman</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>21st-Century hazards of smoking and benefits of cessation in the United States</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>368</volume>(<issue>4</issue>):<fpage>341</fpage>-<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMsa1211128</pub-id><pub-id pub-id-type="pmid">23343063</pub-id></mixed-citation></ref><ref id="abr240008r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lubetkin</surname><given-names>E</given-names></string-name></person-group>. <article-title>Use of a microsimulation method for assessing dynamics of smoking status and gains in life expectancy after quitting in a longitudinal cohort of US older adults</article-title>. <source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>(<issue>11</issue>):<elocation-id>e062189</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2022-062189</pub-id><pub-id pub-id-type="pmid">36332957</pub-id><pub-id pub-id-type="pmcid">PMC9639091</pub-id></mixed-citation></ref><ref id="abr240008r15"><label>15</label><mixed-citation publication-type="journal"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. <article-title>Cigarette smoking among adults and trends in smoking cessation&#8212;United States, 2008</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2009</year>;<volume>58</volume>(<issue>44</issue>):<fpage>1227</fpage>-<lpage>1232</lpage>.<pub-id pub-id-type="pmid">19910909</pub-id></mixed-citation></ref><ref id="abr240008r16"><label>16</label><mixed-citation publication-type="webpage"><person-group><collab>Health Canada</collab></person-group>. Canada Vigilance adverse reaction online database. Accessed April 11, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp" ext-link-type="uri">https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp</ext-link></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ABR240008-1"><supplementary-material id="note-ABR240008-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>eMethods. Supplemental Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e242647-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>Mathematical Model Calculations</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e242647-s002.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>Data Sharing Statement</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e242647-s003.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article></pmc-articleset>